Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Ixion Blotechnology, Inc.
Application No./Patent No.: PCT/US04/009624 Filed/Issue Date: SEPTEMBER 26, 2005
Entitled: METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS TO THE PANCREATIC PATHWAY
XION BIOTECHNOLOGIES. INC.
states that it is: 1. the assignee of the entire right, title, and interest; or
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%
in the patent application/patent identified above by virtue of either:
A A assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR
ON A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From: To:
From:
2. From: To: To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
3. From:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]
The understyped (whose) it is supplied below) is authorized to act on behalf of the assignee.
1/30/07 Date Signature 3864(2-2898
Printed or Typed Name Telephone Number
Title

This collection of information is required by 37 CEON 27(b). The information is required to obtain or retain a benefit by this public which is to file (set by the USPFO to process) an application. Confedentable is governed by 59 US C. 122 and 37 CPR 141 and 1.14. This collection is estimated to late its minused to complete, including gathering, preparing, and submitting the completed application from to the USPFO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or sungestessing for reducing this burder, should be sent to the information Officer. U.S. Patest and Trademark Office. U.S. Department of the complete of the c

ASSIGNMENT

WHEREAS, the undersigned inventor (referred to, collectively, if more than one, as "Assignor") have made an invention entitled Method for Transdifferentiation of Non-Pancreatic Stem Cells to the Pancreatic Pathway for which an application for United States Letters Patent was filed on September 26, 2005 as Application Serial No. 10/550,720 the U.S. national phase of PCT Application No. PCT/US2004/009624, and

WHEREAS, Ixion Biotechnology, Inc., a Delaware Corporation ("Assignee") having a place of business at 13709 Progress Blvd., Box 13, Suite N-111, Alachua, FL 32615, desires to acquire all right, title and interest in and to the above identified invention and application;

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, does hereby sell, assign, convey and transfer unto Assignee all right, title and interest in and to the above identified invention and application, together with all corresponding foreign applications and patents which may be filed thereon, including the right to claim priority from the above identified United States application; and Assignor hereby agrees that Assignor will sign all lawful papers, including, without limitation, all divisional, continuation, renewal, extension and reissue applications, and make all rightful oaths in execution thereof, and will generally do everything possible to aid Assignee, its successors, assigns and nominees to obtain and enforce proper protection for the invention in all countries, this obligation to be binding upon Assignor (each and severally, if more than one) and upon Assignor's personal representative or other legal successor.

tary Public